⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101928 | 1.00 | — | — | |
| SCHEMBL5027780 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL6105178 | 0.97 | — | — | |
| SCHEMBL20980401 | 0.85 | TSHR (0.43) | — | |
| SCHEMBL20682986 | 0.85 | TSHR (0.43) | — | |
| SCHEMBL56311 | 0.82 | ANPEP (0.65) | — | |
| SCHEMBL16843594 | 0.82 | — | — | |
| SCHEMBL10588655 | 0.82 | — | — | |
| SCHEMBL23889238 | 0.81 | TSHR (0.39) | — | |
| SCHEMBL25276038 | 0.81 | ANPEP (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065437-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-20 | — | — | US | disclosed |
| US-20180093992-A1 | PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME LLC | 2018-04-05 | — | — | US | disclosed |
| US-9902703-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. | 2018-01-25 | — | — | US | disclosed |
| EP-2822555-B1 | INHIBITION OF ADAPTOR ASSOCIATED KINASE 1 FOR THE TREATMENT OF PAIN | LEXICON PHARMACEUTICALS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3044226-B1 | ARYL ETHER-BASE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9751887-B2 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-20170001966-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2017-01-05 | — | — | US | disclosed |
| US-20160333006-A1 | ARYL LACTA KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160326111-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2016-11-10 | — | — | US | disclosed |
| US-8969564-B2 | Aryl ether-base kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20150051190-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| US-8901305-B2 | Aryl lactam kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| WO-2014130258-A1 | 5H-CHROMENO[3,4-C]PYRIDINES AS INHIBITORS OF ADAPTOR ASSOCIATED KINASE 1 (AAK1) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20140179725-A1 | Aryl Ether-Base Kinase Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140080834-A1 | INHIBITION OF ADAPTOR ASSOCIATED KINASE 1 FOR THE TREATMENT OF PAIN | LEXICON PHARMACEUTICALS, INC. | 2014-03-20 | — | — | US | disclosed |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | PURDUE PHARMA L.P. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130237555-A1 | Aryl Ether-Base Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2013134036-A1 | ARYL ETHER-BASE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013134336-A2 | INHIBITION OF ADAPTOR ASSOCIATED KINASE 1 FOR THE TREATMENT OF PAIN | LEXICON PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | WO | disclosed |